Special Issue "AIDS Vaccine 2014"
Deadline for manuscript submissions: 1 May 2014
Prof. Dr. Feng Gao
Duke University Medical Center, Human Vaccine Institute, 109B Research Park I, DUMC 103020, NC 27710, USA
Phone: +1 919 668 6433
Fax: +1 919 668 6435
Interests: HIV; genetic variation and evolution; vaccine; drug resistance
A few decades after the discovery of human immunodeficiency viruses as the causal pathogens for AIDS, an effective AIDS vaccine has not be successfully developed to curb the global epidemic of HIV infections. HIV employs many tactics to prevent induction of protective T and B cell immune responses. Facing such a huge challenge, we hope this "AIDS Vaccine" special issue will offer a platform for publication of cutting-edge results in the AIDS vaccine research field.
Previous Special Issue Published in Viruses: "AIDS Vaccine"
Prof. Dr. Feng Gao
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed Open Access monthly journal published by MDPI.
- cell mediated immune response
- genetic variation
Viruses 2014, 6(2), 391-403; doi:10.3390/v6020391
Received: 22 November 2013; in revised form: 7 January 2014 / Accepted: 20 January 2014 / Published: 27 January 2014| Download PDF Full-text (1030 KB) | View HTML Full-text | Download XML Full-text
Viruses 2013, 5(9), 2062-2078; doi:10.3390/v5092062
Received: 2 June 2013; in revised form: 5 August 2013 / Accepted: 22 August 2013 / Published: 28 August 2013| Download PDF Full-text (213 KB) | View HTML Full-text | Download XML Full-text
Opinion: Is a Pacific Coexistence Between Virus and Host the Unexploited Path That May Lead to an HIV Functional Cure?
Viruses 2013, 5(2), 753-757; doi:10.3390/v5020753
Received: 11 January 2013; in revised form: 12 February 2013 / Accepted: 15 February 2013 / Published: 21 February 2013| Download PDF Full-text (164 KB) | View HTML Full-text | Download XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Pseudo-mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines
Authors: Angela Berzi, Norbert Varga, Sara Sattin, Patrizio Antonazzo, Mara Biasin, Irene Cetin, Daria Trabattoni, Anna Bernardi and Mario Clerici
Abstract: The development of new and effective adjuvants may have a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably TLRs. Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand PM 19 to modulate innate immune responses. Results showed that PM 19 alone or in combination with TLR agonists induces the expression of cytokines, β chemokines and co-stimulatory molecules, that may in turn modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated.
Last update: 3 February 2014